Regenerating Bone defects using New biomedical Engineering approaches
Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite t...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
REGENERBONE
REGENERATING LARGE BONE DEFECTS
150K€
Cerrado
DPI2017-82501-P
REPARACION DE GRANDES DEFECTOS OSEOS: TRANSPORTE OSEO VERSUS...
123K€
Cerrado
MAGISTER
Magnetic Scaffolds for in vivo Tissue Engineering
11M€
Cerrado
EEBB-I-12-05306
DISEÑO Y VALIDACION EXPERIMENTAL DE UN NUEVO CONCEPTO DE AND...
10K€
Cerrado
BIO-INSPIRE
BIO INSPIRED BONE REGENERATION
4M€
Cerrado
CHARME
Growing bone fast and cost effective
3M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autografts account for more than 80% of total graft volume. Significant growth opportunities exist for synthetic bone grafts in association with mesenchymal stem cells from autologous or allogenic sources as alternatives to biological bone grafts in orthopaedic and maxillofacial surgery. The objectives of REBORNE is to perform clinical trials using advanced biomaterials and cells triggering bone healing in patients. In order to reach this goal, five phase II clinical studies with 20 patients are proposed in 12 clinical centres spread in 8 European countries. Three orthopaedic trials concerning the treatment of long bone fractures and osteonecrosis of the femoral head in adults or children will be conducted using bioceramics, hydrogel for percuteneous injection and stem cells from autologous or allogenic sources. Clinical research will also concern maxillofacial surgery with bone augmentation prior to dental implants and the reconstruction of cleft palates in children. The safety and efficacy of the new therapies will be assessed clinically using X-rays, CT scans and MRI as well as histology of biopsies. These ambitious clinical targets will require research and development efforts from a large consortium of top world class laboratories, SMEs manufacturing biomaterials, GMP-cell producing facilities and surgeons in hospitals as well as the consideration of ethical and regulatory issues. It is expected that REBORNE will expand the competitiveness of Europe through the patenting of new CE-marked bioproducts in the field of regenerative medicine.